|Chemical and physical data|
|Molar mass||403.898 g/mol g·mol−1|
|3D model (JSmol)|
Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.
On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|